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Background and purpose — There is still no consen-
sus on whether to use thromboprophylaxis as a standard 
treatment in shoulder replacement surgery. We investigated 
the use of thromboprophylaxis reported to the Norwegian 
Arthroplasty Register (NAR). The primary endpoint was 
early mortality after primary shoulder arthroplasty with 
and without thromboprophylaxis. Secondary endpoints 
included revisions within 1 year and intraoperative com-
plications.
Patients and methods — This observational study 
included 6,123 primary shoulder arthroplasties in 5,624 
patients reported to the NAR from 2005 to 2018. Cox regres-
sion analyses including robust variance analysis were per-
formed with adjustments for age, sex, ASA score, diagnosis, 
type of implant, fixation, duration of surgery, and year of 
primary surgery. An instrumental variable Cox regression 
was performed to estimate the causal effect of thrombopro-
phylaxis.
Results — Thromboprophylaxis was used in 4,089 out 
of 6,123 shoulder arthroplasties. 90-day mortality was simi-
lar between the thromboprophylaxis and no thrombopro-
phylaxis groups (hazard ratio (HR) = 1.1, 95% CI 0.6–2.4). 
High age (> 75), high ASA class (≥ 3), and fracture diagnosis 
increased postoperative mortality. No statistically significant 
difference in the risk of revision within 1 year could be found 
(HR = 0.6, CI 0.3–1.2). The proportion of intraoperative 
bleeding was similar in the 2 groups (0.2%, 0.3%).
Interpretation — We had no information on cause of 
death and relation to thromboembolic events. However, no 
association of reduced mortality with use of thromboprophy-
laxis was found. Based on our findings routine use of throm-
boprophylaxis in shoulder arthroplasty can be questioned.
Shoulder arthroplasty (SA) has gained wide acceptance as 
treatment for a variety of shoulder conditions, and the annual 
incidence rates are increasing (Lubbeke et al. 2017). Venous 
thromboembolism (VTE) is a recognized complication after hip 
and knee arthroplasties (Lie et al. 2002) but has been consid-
ered rare after SA. The number of reports of VTE after SA has 
increased with increasing number of SAs performed (Lyman et 
al. 2006, Jameson et al. 2011) and fatal outcome has also been 
reported (Saleem and Markel 2001, Madhusudhan et al. 2009). 
The true risk of VTE after SA has not been determined, and 
even though some studies suggest that the risk equals that of 
lower limb arthroplasty (Willis et al. 2009), most studies find 
a lower risk in the upper extremities (Isma et al. 2010, Saleh 
et al. 2013). Chemical thromboprophylaxis reduces the rates 
of symptomatic VTE following lower limb arthroplasty and is 
supposed to reduce mortality from thromboembolic compli-
cations (Dahl 1998, Senay et al. 2018). Thromboprophylaxis 
remains controversial among surgeons because it may carry a 
higher risk of bleeding, wound complication, and reoperation 
after orthopedic surgery (Kwong et al. 2012).
Guidelines on thromboprophylaxis exist in Norway and in 
other countries (SIGN 2010, Falck-Ytter et al. 2012, Kris-
tiansen et al. 2014, National Institute for Health and Clini-
cal Excellence 2018, Samama et al. 2018). While throm-
boprophylaxis is recommended for all patients undergoing 
hip or knee arthroplasties, there are still no evidence-based 
guidelines specific for SA. Due to the low number of SAs 
performed and the low rate of deaths due to thromboembolic 
events, a randomized trial would not be feasible. Hence, 
the best option to study the effect of thromboprophylaxis is 
large cohort studies (Fender et al. 1997). Using an observa-
tional population-based design with data from the Norwegian 
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Arthroplasty Register (NAR) we studied the use of thrombo-
prophylaxis in patients undergoing SA. Our primary endpoint 
was the influence of thromboprophylaxis on 90-day mortal-
ity. Secondary endpoints were intraoperative bleeding com-
plications and revision due to all causes and due to infection 
within 1 year.  
Patients and methods
This study was performed according to the Reporting of stud-
ies Conducted using the Observational Routinely collected 
health Data (RECORD) checklist. 
The NAR started collecting data on shoulder arthroplasties 
in 1994. All hospitals in Norway performing SAs report to 
the register (Fevang et al. 2009). After each operation the sur-
geon fills in a 1-page paper form, which includes details on the 
surgical procedure and implants with catalogue numbers. In 
addition, the form includes information on age, sex, indication 
for operation, duration of surgery, and intraoperative compli-
cations including major bleeding. From 2005 information also 
includes details on chemical thromboprophylaxis and comor-
bidity according to the ASA classification. The completeness 
of reporting of primary SAs in the NAR was 95% for primary 
operations compared with the Norwegian Patient Registry in 
2017–2018 (Furnes et al. 2020). 
All patients operated on with SA in the period studied were 
included regardless of the cause for operation. Rheumatoid 
arthritis, psoriatic arthritis, ankylosing spondylitis, seronega-
tive arthritis, and systemic lupus erythematosus were grouped 
together and categorized as inflammatory arthritis. Several 
diagnoses could be given for each operation, and in cases with 
more than 1 diagnosis we used the hierarchy developed by the 
Nordic Arthroplasty Register Association (NARA) (Rasmus-
sen et al. 2016). 
The NAR uses the unique personal ID given to each inhab-
itant of Norway to link the primary shoulder arthroplasty to 
subsequent revisions and reoperations. Revisions and reop-
erations are reported equivalent to the primary operation. A 
revision is defined as the insertion, exchange, or extraction of 
any of the prosthesis components while a procedure without 
insertion, exchange, or extraction of components is registered 
as a reoperation. Multiple reasons for revision can be marked 
on the form. In cases with more than 1 reason for revision 
the hierarchy developed by the NARA group was used to 
determine 1 main reason for revision. Reoperations without 
the exchange or extraction of components were reported to 
the register from 2011. In our dataset there were no reported 
reoperations.
The NAR was linked to the National Population Register 
and information on death and emigration was available for all 
patients. Deaths in the first 90 days after surgery were defined 
as primary outcome, as deaths after this period were consid-
ered less likely to be related to the index procedure. Reported 
intraoperative bleeding complications and revisions during the 
first year after surgery were also included in the analyses. 
All 6,972 primary shoulder arthroplasties reported to NAR 
in the period 2005–2018 were eligible for inclusion in the 
study. No patients emigrated during the study period. We 
excluded 849 operations with missing information in one or 
more of the variables of interest. Finally 6,123 cases were 
included in the study. 
Statistics
Pearson’s chi-square test was used for comparison of categori-
cal variables. 
Survival time for the 2 subgroups of patients was calculated 
using Kaplan–Meier estimates. Endpoint was death of any 
cause within 90 days. Cox regression analyses were used to 
calculate hazard ratios (HRs) for postoperative deaths and risk 
of revision between patients receiving thromboprophylaxis 
and those not receiving prophylaxis, with adjustments for pos-
sible confounding of age, sex, ASA score, diagnosis, type of 
implant (anatomic total, reversed, or hemiarthroplasty), fixa-
tion (cemented or uncemented humerus stem), duration of sur-
gery, and year of surgery. 
Bilateral cases were treated in the descriptive part as if they 
were independent, while the adjusted HRs were calculated 
using robust variance estimates to account for bilateral SAs. 
Calculation of the robust variance estimates follows the count-
ing process formula of Andersen and Gill (Andersen and Gill 
1982, Therneau and Grambsch 2000).
As an alternative to the adjusted Cox regression, we esti-
mated the causal effect of thromboprophylaxis using an 
instrumental variable (IV) approach. This analysis follows the 
methods described by MacKenzie et al. (2014) for IVs in a 
Cox regression model using the statistical package R (R Foun-
dation for Statistical Computing, Vienna, Austria). As instru-
ment, we applied the hospital’s annual propensity for using 
thrombosis prophylaxis. Hence, the IV approach assumes that 
the hospital is related to the mortality only through the use of 
thrombosis prophylaxis, and that the hospital is independent 
of unobserved covariates. Under these conditions the esti-
mated HR can be interpreted as a causal HR of thrombosis 
prophylaxis on mortality.
All tests were 2-sided and p-values below 0.05 were consid-
ered statistically significant. 
Follow-up started on the day of the primary arthroplasty 
and ended on the date of death or at 90 days for the mortality 
analyses and at 1 year after surgery for the revision analyses. 
All analyses were repeated stratifying on age, sex, ASA clas-
sification, diagnosis, and arthroplasty type in order to study 
the potential differences in effect of thromboprophylaxis on 
outcomes in subgroups of patients. 
Analyses were performed using the package IBM SPSS sta-
tistics version 24.0 (IBM Corp, Armonk, NY, USA) and the 
statistical package R Version 4.0.0 (R Foundation, Vienna, 
Austria). 
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Results
4,089 cases received thromboprophylaxis and 2,034 did not 
receive thromboprophylaxis. Low molecular weight heparin 
(LMWH) was the dominant medication used. 2,778 patients 
were treated with dalteparin and 1,201 patients with enoxapa-
rin (68% and 29% of the patients receiving thromboprophy-
laxis respectively). 
Patient and procedure characteristics for the 2 groups are 
shown in Table 1. The patients receiving thromboprophylaxis 
had statistically significantly higher mean ASA class and 
longer mean duration of surgery. Patients operated on with a 
reverse shoulder arthroplasty (RSA) more frequently received 
thromboprophylaxis compared with patients operated on with 
stemmed hemiarthroplasty (SHA) and total shoulder arthro-
plasty (TSA) (p < 0.001). 
There was an increase in the use of thromboprophylaxis 
over time in the period studied (Figure 1). The use of hemiar-
throplasty dominated in the earlier years of this period, and the 
use of RSAs and TSAs increased in the later years (Figure 2). 
Risk of death 
We identified 50 deaths within 90 days in the period studied, 
35 in the thromboprophylaxis group and 15 in the group with 
no thromboprophylaxis (Figure 3). Adjusted HR showed no 
significant difference between the two groups (HR 1.2; CI 
0.6–2.2) with the no thromboprophylaxis group as reference. 
Using the IV approach, we found a non-significant causal 
effect of thromboprophylaxis on 90-day mortality (HR 1.1; CI 
0.6–2.4) (Table 2).
Table 1. Patient and procedure characteristics at primary shoulder 
arthroplasties relative to thromboprophylaxis or no thromboprophy-
laxis reported to the Norwegian Arthroplasty Register 2005–2018
 Thromboprophylaxis
Factor No Yes p-value
Number of procedures 2,034 (33) 4,089 (67) 
Women  1,429 (70) 2,846 (70) 0.6 a
Mean age at surgery (SD) 70.7 (10.8) 70.9 (10.7) 0.6 b
Age group    0.07 a
 ≤ 64 years  568 (28) 1,035 (25) 
 65–74 years  697 (34) 1,484 (36) 
 ≥ 75 years  769 (38) 1,570(38) 
ASA class   0.02 a
 1–2 1,329 (65) 2,546 (62) 
 3–4 705 (35) 1,543 (38) 
Arthroplasty type   < 0.001 a
 TSA 355 (18) 887 (22) 
 RSA 816 (40) 1,957 (48) 
 SHA 623 (31) 965 (24) 
 Other 240 (12) 280 (7) 
Diagnosis   0.01 a
 Primary arthritis 740 (36) 1,584 (39) 
 Acute fracture 583 (29) 1,068 (26) 
 Fracture sequelae 294 (15) 578 (14) 
 Rotator cuff arthropathy 193 (9.5) 323 (7.9) 
 Inflammatory arthritis 156 (7.7) 357 (8.7) 
 Other  68 (3.3) 179 (4.4) 
Duration of surgery
 in minutes, mean (SD) 109 (42) 114 (37) < 0.001 b 
Fixation of stem   < 0.001 a
 Cemented 895 (44) 2,396 (59) 
 Uncemented  1,139 (56) 1,693 (41) 
TSA = total shoulder arthroplasty, RSA = reverse shoulder arthro-
plasty, SHA = stemmed hemiarthroplasty.
a Pearson’s chi-square test; 
b Student’s t-test.
Figure 1. Change in the use of thromboprophylaxis over time, Norwe-
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Figure 2. Change in the use of different arthroplasty design over time, 
Norwegian Arthroplasty Register 2005–2018.
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Compared with patients with primary osteoarthritis, patients 
with acute fractures had a higher 90-day mortality (HR 3.4; 
CI 1.2–9.5). A similar tendency was found for patients with 
sequelae after fracture, but the difference was not statistically 
significant. Patients with rotator cuff arthropathy or inflam-
matory arthritis did not have increased 90-day mortality com-
pared with patients with primary osteoarthritis (Table 3, see 
Supplementary data). We found higher 90-day mortality after 
fracture-related surgery (acute fracture and fracture sequelae) 
than after non-fracture-related surgery 1.6% (CI 1.0–2.2) vs. 
0.3% (CI 0.1–0.5).
Old age (> 75 years), high ASA class (≥ 3), and acute frac-
ture diagnosis statistically significantly increased 90-day mor-
tality. The risk of death was not significantly changed in the 
different time periods studied (Table 3, see Supplementary 
data).
ASA classification and age
Since both increasing ASA class and high age increased mor-
tality, we also performed Cox regression analysis with patients 
stratified into 3 different risk groups, dependent on both age 
(≥ 80 based on the Norwegian guidelines for thromboprophy-
laxis) and ASA classification. This analysis suggested an even 
stronger correlation between age, ASA class, and the risk of 
death. We found no statistically significant difference in the 
distribution of thromboprophylaxis in the different risk groups 
and use of thromboprophylaxis did not alter the risk of death 
at 90 days (Table 4, see Supplementary data). 
Revision risk
There were 155 revisions within the first year. Of these, 29 
revisions were performed due to deep infections (16 in the 
thromboprophylaxis group and 13 in the no thromboprophy-
laxis group). 62 revisions were due to loosening of 1 or more 
of the components without deep infection recorded. Risks of 
revision of any cause (HR 0.8; CI 0.6–1.1) and for infection 
(HR 0.6; CI 0.3–1.2) were similar between the study groups 
(Table 5, see Supplementary data, Figure 4). No reoperations 
were recorded.
Intraoperative complications
182 intraoperative complications were registered. Extensive 
intraoperative bleeding was reported in 17 cases, 12 in the 
thromboprophylaxis group (0.3%) and 5 in the no throm-
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Figure 3. Kaplan–Meier curve showing the 
death rate up to 90 days after surgery in 
patients with and without thromboprophylaxis 
with 95% CI.
Figure 4. Kaplan–Meier curve showing the revision rate due to all causes (A) and due to infection 
(B) up to 1 year with 95% CI. 
Table 2. Kaplan–Meier (K–M) estimated risk of death at 90 days: shoulder arthroplasties reported 
to the Norwegian Arthroplasty Register 2005–2018
 Deaths At risk K–M % deaths Adjusted IV adjusted
 at 90 days at 90 days  (95% CI) HR (95% CI) HR (95% CI)
No thromboprophylaxis 15 1,928 0.8 (0.4–1.2) 1 1
Thromboprophylaxis 35 3,859 0.9 (0.7–1.1) 1.2 (0.6–2.1) 1.1 (0.6–2.4)
Cox adjusted hazard ratio (HR) with robust variance estimates adjusted for age, sex, ASA class, 
diagnosis, arthroplasty type, use of cement in humerus, duration of surgery and time period.
IV = Instrument variable approach.
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boprophylaxis group (0.2%). Only 3 of the 12 patients with 
extensive bleeding in the thromboprophylaxis group had pre-
operative initiation of the thromboprophylaxis.  
Discussion
Our main finding was that there was no association between 
the use of thromboprophylaxis and the risk of death in the post-
operative period. As expected, we found that high age, high 
ASA class, and fracture diagnosis (acute fracture and fracture 
sequelae) increased the 90-day mortality. Earlier studies on 
thromboprophylaxis in shoulder arthroplasty surgery include 
fewer patients, and even though the number of deaths in our 
study is low the incidence is comparable to earlier studies. 
Thromboprophylaxis after shoulder surgery is still a con-
troversial issue: the national guidelines in Norway and other 
countries are vague. The guidelines in the United Kingdom 
(National Institute for Health and Clinical Excellence 2018) 
recommends that the surgeon “Consider VTE prophylaxis for 
people undergoing upper limb surgery if the person’s total 
time under general anaesthetic is over 90 minutes or where 
their operation is likely to make it difficult for them to mobil-
ise.” Based on these recommendations the vast majority of 
shoulder arthroplasty patients will require thromboprophy-
laxis. However, VTE events are rare after planned shoulder 
surgery (0.01–0.5%) (Lyman et al. 2006, Jameson et al. 2011, 
Navarro et al. 2013).
In the study from Jameson et al. (2011) the 90-day mortality 
rates after planned shoulder surgery were low (0.03–0.5%), 
and no change in the mortality rate after the introduction of 
the 2007 NICE guidelines could be found. Our results with 
0.3% 90-day mortality in non-fracture SA surgery support 
Jameson’s findings.
VTE events are more common in the proximal humerus 
fracture setting (0.4–1.7%) (Navarro et al. 2013) but com-
pared with other orthopedic procedures the risk is still low 
(Dahl et al. 2003). 
In a large cohort study from Young et al. (2015) proxi-
mal humerus fracture, anemia, congestive heart failure, and 
chronic lung disease were 4 independent predictors for PE 
after shoulder arthroplasty. As expected, increasing age, frac-
ture diagnosis, and high ASA class correlated with increased 
mortality in our cohort. 
We found increased use of thromboprophylaxis in shoulder 
arthroplasty surgeries during the studied period. The Norwe-
gian guidelines (Kristiansen et al. 2014) indicating that throm-
boprophylaxis should be used have probably led to some hos-
pitals changing their use of prophylaxis, but some hospitals 
were not consistent in their use of prophylaxis. This may be 
explained by surgeon’s preference or by lack of routines. It 
could also reflect diversified treatment where patients consid-
ered at risk are given thromboprophylaxis. The use does not 
seem to correlate with the patient’s ASA class, but the ASA 
class does not fully account for risk factors like previous DVT 
or other predisposing factors and may therefore not necessar-
ily be a good measure of the actual risk of VTE and mortality. 
In our study the use of different arthroplasty types changed 
during the period studied and some of the differences in the 
use of thromboprophylaxis in different arthroplasties can be 
explained by the change of indications for the arthroplasty 
type. 
The lack of consensus on the use of prophylaxis in shoulder 
replacement surgery is reflected by our data, where some hos-
pitals seem to give thromboprophylaxis as a routine and others 
do not. Some hospitals perform more elective surgery and have 
more rheumatoid patients while other perform more fracture 
surgery, and this may also influence the hospital’s routines for 
thromboprophylaxis. The cost-effectiveness of daily injec-
tions of LMWH has to be considered. It is inconvenient for 
the patient and resource demanding for the healthcare system 
if patients cannot administer the injections themselves, and 
there are potential complications. However, we found no dif-
ference in intraoperative bleeding complications between the 
2 groups and the use of thromboprophylaxis did not seem to 
affect the risk of revision due to infection. Kwong et al. (2012) 
found insufficient data in the literature to confirm or refute 
the hypothesis that postoperative bleeding due to VTE pro-
phylaxis in hip and knee arthroplasty contributes to increased 
risk for wound infection. 
Navarro et al. (2013) observed no difference in 90-day mor-
tality by procedure type (reverse shoulder arthroplasties, total 
shoulder arthroplasties, or hemiarthroplasties), but a higher 
mortality in trauma patients compared with elective in his ret-
rospective database review from the Kaiser Permanente reg-
istry. In our cohort we found increased risk of mortality in 
the acute fracture setting, and use of thromboprophylaxis did 
not alter this risk. Navarro found that only 1 of the 13 deaths 
observed in his study could be attributed to complications of 
PE, and this indicates that this is a fragile group of patients 
with several comorbidities and increased risk of death. In 
accordance with this we found increased risk of death in the 
acute fracture group and also higher age in this group.
By dividing patients into risk groups and combining the 
ASA classification with age, Dale et al. (2020) showed that 
high-risk patients had nearly 9 times the risk of adjusted peri-
operative death after primary total hip arthroplasty compared 
with low-risk patients. In our study the use of thrombopro-
phylaxis did not alter the risk of death within 90 days in any 
of the risk groups. This does not support the routine use of 
thromboprophylaxis to prevent death. 
The bilateral observations in register studies can be dealt 
with in different ways (Ranstam et al. 2011). Also, Lie et al. 
(2004) studied the influence of bilateral hip arthroplasties on 
survival analyses and concluded that in analyses of arthro-
plasty survival dependencies should be considered, but ignor-
ing the possible dependencies does not necessarily have an 
impact on the result. We performed Cox regression analyses 
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with robust variance analyses to account for the bilateral cases 
and found only small differences (statistically non-significant) 
between unadjusted and adjusted risk of death. Using an 
instrument variable analysis approach to estimate the causal 
effect of thrombosis prophylaxis confirmed the results from 
the standard analysis. 
Strengths and limitations
This is a nationwide observational cohort study from the Nor-
wegian Arthroplasty Register. The strengths of a register study 
are the large number of patients and the possibility to study 
rare events. All hospitals performing shoulder arthroplasties 
in Norway are reporting to the register and the completeness 
of reporting primary cases is 95% (Furnes et al. 2020). Infor-
mation on death and migration was available from Statistics 
Norway, allowing for nationwide cohort studies with complete 
follow-up. We do not, however, have access to the cause of 
death or readmissions to hospital due to VTE or bleeding in 
these patients. Lie et al. (2002) studied 67,000 hip arthroplas-
ties and early postoperative mortality by linkage to the cause 
of death registry. They found that vascular causes of death 
were commonest, with the subcategory thromboembolic com-
plications as the most frequent cause. Even though we do not 
have access to cause of death in our material we might assume 
that thromboembolic complications are also a common cause 
of death in shoulder arthroplasty surgery. This is confirmed 
in a study from the Danish Shoulder Arthroplasty Registry 
(Amundsen et al. 2016). They reported the 90-day mortality 
and the reasons for death between 2006 and 2012. In their 
study, approximately 30% of deaths were reported with a car-
diac or pulmonary cause. In light of the results from Amund-
sen’s study we can assume that the number of deaths related 
to thromboembolic events in our study, with only 35 and 15 
deaths in the 2 groups, were low and probably insufficient to 
make any clear recommendations.
The use of thromboprophylaxis as a standard method of 
treatment varies among hospitals. This might influence the 
result, as different surgeons may have different results. The 
instrumental variable analysis accounted for these differences 
by applying the hospitals’ propensity for using thrombopro-
phylaxis in the model and the results from the standard analy-
sis were confirmed. 
An intraoperative bleeding complication was recorded only 
if the surgeon considered it to be extensive, and the amount of 
bleeding was not recorded. The completeness of the registra-
tion of complications has not been investigated. The findings 
regarding intraoperative complications must hence be inter-
preted with caution, and the incidence of such complications 
is most likely higher than reported. Until 2011, reoperation 
due to bleeding or hematoma was not reported to the register 
unless a revision of the prosthesis was also performed. From 
2011 all reoperations should be reported to the register, but 
the completeness of this registration is not known and may be 
underreported.
Conclusion 
The use of thromboprophylaxis does not seem to reduce the 
overall low mortality and the use of thromboprophylaxis as a 
routine in shoulder arthroplasty surgery to prevent thrombo-
embolic complications leading to death can be discussed. We 
cannot exclude that subgroups of patients with a high risk of 
VTE, such as earlier VTE events, may benefit from thrombo-
prophylaxis. 
Supplementary data
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sion of this article, http://dx.doi.org/10.1080/17453674.2021. 
1906595
RMH performed the analyses of the data and wrote the manuscript. AMF 
and SAL contributed with statistical advice. All authors contributed to the 
conception and design of the study, critical analyses of the data, interpreta-
tion of the findings, and critical revision of the manuscript through all stages 
of the study.
The authors would like to thank the Norwegian surgeons for their contribu-
tion by thoroughly reporting to the NAR and the staff at the NAR for their 
meticulous punching and statistical advice.
Acta thanks Lars Adolfsson and Jeppe Vejlgaard Rasmussen for help 
with peer review of this study.
Amundsen A, Rasmussen J V, Olsen B S, Brorson S. Mortality after 
shoulder arthroplasty: 30-day, 90-day, and 1-year mortality after shoulder 
replacement—5853 primary operations reported to the Danish Shoulder 
Arthroplasty Registry. J Shoulder Elbow Surg 2016; 25(5): 756-62. doi: 
10.1016/j.jse.2015.09.020.
Andersen P K, Gill R. Cox’s regression model for counting processes: a 
large sample study. Annals of Statistics 1982; 10(4): 1100-20.
Dahl O E. Thromboprophylaxis in hip arthroplasty: new frontiers 
and future strategy. Acta Orthop Scand 1998; 69(4): 339-42. doi: 
10.3109/17453679808999042.
Dahl O E, Gudmundsen T E, Bjornara B T, Solheim D M. Risk of clini-
cal pulmonary embolism after joint surgery in patients receiving low-
molecular-weight heparin prophylaxis in hospital: a 10-year prospective 
register of 3,954 patients. Acta Orthop Scand 2003; 74(3): 299-304. doi: 
10.1080/00016470310014229.
Dale H, Borsheim S, Kristensen T B, Fenstad A M, Gjertsen J E, Hallan 
G, Lie S A, Furnes O. Perioperative, short-, and long-term mortality 
related to fixation in primary total hip arthroplasty: a study on 79,557 
patients in the Norwegian Arthroplasty Register. Acta Orthop 2020; 91(2): 
152-8. doi: 10.1080/17453674.2019.1701312.
Falck-Ytter Y, Francis C W, Johanson N A, Curley C, Dahl O E, Schul-
man S, Ortel T L, Pauker S G, Colwell C W Jr. Prevention of VTE in 
orthopedic surgery patients: antithrombotic therapy and prevention of 
thrombosis, 9th ed: American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines. Chest 2012; 141(2 Suppl.): e278S-e325S. 
doi: 10.1378/chest.11-2404.
Fender D, Harper W M, Thompson J R, Gregg P J. Mortality and fatal 
pulmonary embolism after primary total hip replacement: results from a 
regional hip register. J Bone Joint Surg Br 1997; 79(6): 896-9.
Fevang B T, Lie S A, Havelin L I, Skredderstuen A, Furnes O. Risk factors 
for revision after shoulder arthroplasty: 1,825 shoulder arthroplasties from 
the Norwegian Arthroplasty Register. Acta Orthop 2009; 80(1): 83-91. doi: 
10.1080/17453670902805098.
Acta Orthopaedica 2021; 92 (4): 401–407 407
Furnes O, Hallan G, Visnes H, Gundersen T, Kvinnesland I A, Fenstad A 
M, Dybvik E, Kroken G. Annual report: the Norwegian Advisory Unit on 
Arthroplasty and Hip Fractures; 2020. doi: 10.13140/RG.2.2.18876.46727
Isma N, Svensson P J, Gottsater A, Lindblad B. Upper extremity deep 
venous thrombosis in the population-based Malmo thrombophilia study 
(MATS): epidemiology, risk factors, recurrence risk, and mortality. Thromb 
Res 2010; 125(6): e335-8. doi: 10.1016/j.thromres.2010.03.005.
Jameson S S, James P, Howcroft D W, Serrano-Pedraza I, Rangan A, 
Reed M R, Candal-Couto J. Venous thromboembolic events are rare after 
shoulder surgery: analysis of a national database. J Shoulder Elbow Surg 
2011; 20(5): 764-70. doi: 10.1016/j.jse.2010.11.034.
Kristiansen A, Brandt L, Berge E, Dahm A E, Halvorsen S, Sandset P M, Vand-
vik P O. [New guidelines for antithrombotic therapy and thromboprophylaxis]. 
Tidsskr Nor Laegeforen 2014; 134(9): 921-2. doi: 10.4045/tidsskr.13.1582.
Kwong L M, Kistler K D, Mills R, Wildgoose P, Klaskala W. Thrombo-
prophylaxis, bleeding and post-operative prosthetic joint infection in total 
hip and knee arthroplasty: a comprehensive literature review. Expert Opin 
Pharmacother 2012; 13(3): 333-44. doi: 10.1517/14656566.2012.652087.
Lie S A, Engesaeter L B, Havelin L I, Furnes O, Vollset S E. Early postop-
erative mortality after 67,548 total hip replacements: causes of death and 
thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta 
Orthop Scand 2002; 73(4): 392-9. doi: 10.1080/00016470216312.
Lie S A, Engesaeter L B, Havelin L I, Gjessing H K, Vollset S E. Depen-
dency issues in survival analyses of 55,782 primary hip replacements from 
47,355 patients. Stat Med 2004; 23(20): 3227-40. doi: 10.1002/sim.1905.
Lubbeke A, Rees J L, Barea C, Combescure C, Carr A J, Silman A J. 
International variation in shoulder arthroplasty. Acta Orthop 2017; 88(6): 
592-9. doi: 10.1080/17453674.2017.1368884.
Lyman S, Sherman S, Carter T I, Bach P B, Mandl L A, Marx R G. Preva-
lence and risk factors for symptomatic thromboembolic events after shoul-
der arthroplasty. Clin Orthop Relat Res 2006; 448:152-6. doi: 10.1097/01.
blo.0000194679.87258.6e.
MacKenzie T A, Tosteson T D, Morden N E, Stukel T A, O’Malley A 
J. Using instrumental variables to estimate a Cox’s proportional hazards 
regression subject to additive confounding. Health Serv Outcomes Res 
Methodol 2014; 14(1-2): 54-68. doi: 10.1007/s10742-014-0117-x.
Madhusudhan T R, Shetty S K, Madhusudhan S, Sinha A. Fatal pulmo-
nary embolism following shoulder arthroplasty: a case report. J Med Case 
Rep 2009; 3: 8708. doi: 10.4076/1752-1947-3-8708.
National Institute for Health and Clinical Excellence. Venous thrombo-
embolism in over 16s: reducing the risk of hospital-acquired deep vein 
thrombosis or pulmonary embolism (NG89). Available at: www.nice.org.
uk/guidance/ng89. [Guidelines] 2018.
Navarro R A, Inacio M C, Burke M F, Costouros J G, Yian E H. Risk 
of thromboembolism in shoulder arthroplasty: effect of implant type and 
traumatic indication. Clin Orthop Relat Res 2013; 471(5): 1576-81. doi: 
10.1007/s11999-013-2829-6.
Ranstam J, Käarrholm J, Pulkkinen P, Mäkelä K, Espehaug B, Pedersen 
A B, Mehnert F, Furnes O,  NARA study group. Statistical analysis of 
arthroplasty data, II: Guidelines. Acta Orthop 2011; 82(3): 258-67. doi: 
10.3109/17453674.2011.588863.
Rasmussen J V, Brorson S, Hallan G, Dale H, Aarimaa V, Mokka J, 
Jensen S L, Fenstad A M, Salomonsson B. Is it feasible to merge data 
from national shoulder registries? A new collaboration within the Nordic 
Arthroplasty Register Association. J Shoulder Elbow Surg 2016; 25(12): 
e369-e77. doi: 10.1016/j.jse.2016.02.034.
Saleem A, Markel D C. Fatal pulmonary embolus after shoulder arthroplasty. 
J Arthroplasty 2001; 16(3): 400-3. doi: 10.1054/arth.2001.20546.
Saleh H E, Pennings A L, ElMaraghy A W. Venous thromboembolism after 
shoulder arthroplasty: a systematic review. J Shoulder Elbow Surg 2013; 
22 (10): 1440-8. doi: 10.1016/j.jse.2013.05.013
Samama C M, Afshari A, ESA VTE Guidelines Task Force. European 
guidelines on perioperative venous thromboembolism prophylaxis. Eur J 
Anaesthesiol 2018; 35(2): 73-6. doi: 10.1097/EJA.0000000000000702.
Senay A, Trottier M, Delisle J, Banica A, Benoit B, Laflamme G Y, Malo 
M, Nguyen H, Ranger P, Fernandes J C. Incidence of symptomatic 
venous thromboembolism in 2372 knee and hip replacement patients after 
discharge: data from a thromboprophylaxis registry in Montreal, Canada. 
Vasc Health Risk Manag 2018; 14: 81-9. doi: 10.2147/VHRM.S150474.
SIGN (Scottish Intercollegiate Guidelines Network). Prevention and man-
agement of venous thromboembolism. Edinburgh: SIGN;  2010. (SIGN 
publication no 122). [cited 10 Dec 2010]. http://www.sign.ac.uk. [Guide-
lines] 2010.
Therneau T M, Grambsch P M. Modeling survival data: extending the Cox 
model. (ISBN 978-1-4757-3294-8). New York: Springer; 2000.
Willis A A, Warren R F, Craig E V, Adler R S, Cordasco F A, Lyman S, 
Fealy S. Deep vein thrombosis after reconstructive shoulder arthroplasty: 
a prospective observational study. J Shoulder Elbow Surg 2009; 18(1): 
100-6. doi: 10.1016/j.jse.2008.07.011
Young B L, Menendez M E, Baker D K, Ponce B A. Factors associated with 
in-hospital pulmonary embolism after shoulder arthroplasty. J Shoulder 
Elbow Surg 2015; 24(10): e271-8. doi: 10.1016/j.jse.2015.04.002.
